Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More

In spite of their successes, Immuno-oncology products, which we still like to call immunotherapy for several reasons, are a work in progress. The most two highlighted approaches that enable the immune system to clear cancers are the checkpoint inhibition and the chimeric antigen receptor (CAR T) genetically engineered immune system T cells therapies. Therapeutic vaccines had some successes, but the outcome was inferior to the two approaches that have proven to be the game changers in cancer management.

As we said in the beginning, the novel immunotherapy approaches have had some miraculous results, but still . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.